Innovent Biologics Inc (6IB) — Cash Flow-to-Debt Ratio
Innovent Biologics Inc (6IB) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2023, meaning its operating cash flow of €-311.45 Million could theoretically repay 0% of its total liabilities (€7.11 Billion) in one year. See Innovent Biologics Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Innovent Biologics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Innovent Biologics Inc across 10 annual periods. For the full cash flow conversion analysis, see Innovent Biologics Inc (6IB) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Innovent Biologics Inc (2016–2025)
Year-by-year debt coverage analysis for Innovent Biologics Inc. Check Innovent Biologics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.56x | €10.00 Billion | €17.99 Billion | ▲ +266.5% |
| 2024 | 0.15x | €1.29 Billion | €8.48 Billion | ▲ +731.2% |
| 2023 | 0.02x | €147.81 Million | €8.10 Billion | ▲ +106.5% |
| 2022 | -0.28x | €-1.92 Billion | €6.86 Billion | ▲ +18.3% |
| 2021 | -0.34x | €-2.02 Billion | €5.91 Billion | ▼ -240.0% |
| 2020 | -0.10x | €-307.69 Million | €3.06 Billion | ▲ +85.0% |
| 2019 | -0.67x | €-1.66 Billion | €2.47 Billion | ▼ -27.5% |
| 2018 | -0.53x | €-1.01 Billion | €1.92 Billion | ▼ -337.1% |
| 2017 | -0.12x | €-492.27 Million | €4.08 Billion | ▼ -25.5% |
| 2016 | -0.10x | €-362.99 Million | €3.77 Billion | — |